SavedAdd your journal

Journals / Yeni Tıp Dergisi / 2014 / Cilt: 31 - Sayı: 2

Surgical treatment approaches according to the molecular subtypes in breast cancer

Meme kanserinde moleküler alt tiplere göre cerrahi tedavi yaklaşımları

Aydan EROĞLU
Egemen ÇİÇEK
Pages
83–87
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review we discuss whether the new classification according to the molecular subtypes is useful for the surgical treatment approaches and the correlation between the molecular subtypes and prognosis of breast cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Breast cancer is a very common disease and heterogeneous tumor that exhibits very different biological behavior.
📊
Key Findings & Data:Based on cDNA microarrays and immunohistochemical markers, breast cancer is classified into four distinct subtypes: luminal A(estrogen receptor [ER] positive and/or progesterone receptor [PR] positive, human epidermal growth factor receptor 2 [HER2] negative, Ki67 low); luminal B (ER positive and/ or PR positive, HER2 positive, Ki67 high); HER2-enriched (ER negative, PR negative, HER2 positive); and basal-like (ER negative, PR negative, HER2 negative, cytokeratin 5/6 positive).
💡
Conclusion & Impact:In this review we discuss whether the new classification according to the molecular subtypes is useful for the surgical treatment approaches and the correlation between the molecular subtypes and prognosis of breast cancer.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Breast cancer is a very common disease and heterogeneous tumor that exhibits very different biological behavior. Based on cDNA microarrays and immunohistochemical markers, breast cancer is classified into four distinct subtypes: luminal A(estrogen receptor [ER] positive and/or progesterone receptor [PR] positive, human epidermal growth factor receptor 2 [HER2] negative, Ki67 low); luminal B (ER positive and/ or PR positive, HER2 positive, Ki67 high); HER2-enriched (ER negative, PR negative, HER2 positive); and basal-like (ER negative, PR negative, HER2 negative, cytokeratin 5/6 positive). Several studies have investigated the association between survival and the molecular subtypes of breast cancer. It is generally reported that luminal type tumors have a more favorable prognosis but, basallike and HER2-enriched types more likely to develop the recurrence. Recent reports have examined the identified significant difference in treatment strategies in patients of varying molecular subtypes of breast cancer. In this review we discuss whether the new classification according to the molecular subtypes is useful for the surgical treatment approaches and the correlation between the molecular subtypes and prognosis of breast cancer.

Özet

Meme kanseri oldukça sık görülen bir hastalıktır ve farklı biyolojik davranışlar sergileyen heterojen bir tümördür. cDNA mikrodizin çalışması ve immünohistokimyasal belirteçlere dayanarak meme kanseri 4 temel alt tipe ayrılmıştır: luminal A (estrojen reseptör [ER] pozitif ve/ veya progesteron reseptör [PR] pozitif, human epidermal growth factor receptor 2 [HER2] negatif, Ki67 ekspresyonu düşük; luminal B (ER pozitif ve/veya PR pozitif, HER2 pozitif, Ki67 yüksek); HER2-pozitif (ER negatif, PR negatif, HER2 pozitif); ve bazal tip (ER negatif, PR negatif, HER2 negatif, cytokeratin 5/6 pozitif). Son yıllarda bazı çalışmalarda meme kanserinin bu moleküler alt tipleri ile sağ kalım arasındaki ilişki araştırılmıştır. Genel olarak luminal tip tümörler daha iyi prognoza sahip iken, bazal tip ve HER2 pozitif tip meme kanserinde nüks hastalık gelişimi daha fazladır. Yeni çalışmalar meme kanserli olgularda bu farklı alt tipleri arasında tedavi stratejilerinde belirgin farklılıkları göstermektedir. Bu derlemede moleküler alt tiplere göre yapılan bu yeni sınıflamanın cerrahi tedavi yaklaşımları üzerine yararı olup olmadığı ve bu moleküler alt tipler ile meme kanseri prognozu arasında ilişki tartışılmıştır.

🔖

Cite This Article

EROĞLU, A., ÇİÇEK, E. (2014). Surgical treatment approaches according to the molecular subtypes in breast cancer. Yeni Tıp Dergisi, Cilt: 31 - Sayı: 2, 83–87. https://ajindex.com/articles/338376

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Donegan WL. Staging and primary treatment. Donegan WL, Spratt JS (Eds) In: Cancer of the Breast. WB Saunders Company 1995;pp:375-442
  2. Haagensen CD, Stout AP. Carcinoma of the breast: criteria for operability. Ann Surg 1943;118:859
  3. Portmann UV. Clinical and pathologic criteria as a basis for classifying cases of primary cancer of the breast. Cleveland Clin Q 1943; 10:41
  4. Haagensen CD, Bondian C. A personal experience with Halsted’s radical mastectomy. Ann Surg 1984;199:143
  5. Çavuşoğlu AÇ, Saydam S, Canda T, Sakızlı M. Tümör sınıflamasında yenilik çabaları. Meme Sağlığı Dergisi 2009;5:187-90. 6. www.cancerstaging.net. ve TNM online: http://www3.interscience. wiley.com
  6. Veronesia U, Vialeb G, Rotmensza N et al. Breast cancer TNM classification for treatment decision-making research. The Breast 2006; 15:3-8
  7. Hardiman G. Microarray platformscomparisons and contrasts. Pharmacogenomics 2004;5:487-502
  8. Perou CM, Jeffrey SS, Van De Rijn M et al.: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA 1999;96:9212-7
  9. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 2000;406:747-52
  10. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-60
  11. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
  12. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74
  13. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple- negative breast cancer. Cancer 2007;109:25-32
  14. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76
  15. West M, Blanchette C, Dressmann H et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. USA 2001;98:11462-7
  16. Van’t Veer LJ, Dai H, Van De Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6
  17. Zhou W, He Z, Xue J. et al. Molecular subtype classification is a determinant of non-sentinel lymph node metastasis in breast cancer patients w